Comparative Pharmacology
Head-to-head clinical analysis: AROMASIN versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AROMASIN versus TESLAC.
AROMASIN vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible steroidal aromatase inhibitor that binds to the aromatase enzyme, leading to its permanent inactivation via covalent modification. This reduces estrogen biosynthesis (primarily in peripheral tissues) by inhibiting conversion of androgens to estrogens.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
25 mg orally once daily after a meal
250 mg intramuscularly three times per week
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) for exemestane, supporting once-daily dosing. Steady state achieved within 7 days.
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Primarily hepatic metabolism via CYP3A4 and aldoketoreductases, with 60-70% of metabolites excreted renally and 30-40% via feces. Less than 1% excreted unchanged in urine.
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor